Referencia número: HY-N0523

Gallic acid

Name: Gallic acid
Brand: MedChemExpress
SKU: HY-N0523
Price: 25.00 USD
Availability: InStock
Rating: 5 (19 reviews)

(Synonyms: 3,4,5-Trihydroxybenzoic acid)

19 Cited Publications

Revisión del cliente

Based on 19 publication(s) in Google Scholar

Gallic acid (3,4,5-Trihydroxybenzoic acid) is a natural polyhydroxyphenolic compound and an free radical scavenger to inhibit cyclooxygenase-2 (COX-2). Gallic acid has various activities, such as antimicrobial, antioxidant, antimicrobial, anti-inflammatory, and anticance activities.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.99%
No. CAS: 149-91-7
Fòrmula: C₇H₆O₅
Peso molecular:170.12

Almacenamiento:

Store at room temperature 3 years.

In solvent -80°C, 2 years , -20°C, 1 year

Gallic acid Chemical Structure

No. CAS: 149-91-7

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (19)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Gallic acid (3,4,5-Trihydroxybenzoic acid) is a natural polyhydroxyphenolic compound and an free radical scavenger to inhibit cyclooxygenase-2 (COX-2)^[1]. Gallic acid has various activities, such as antimicrobial, antioxidant, antimicrobial, anti-inflammatory, and anticance activities^[2].

IC₅₀ & Target

^[1]

COX-2

Microbial Metabolite

Human Endogenous Metabolite

Ver todos los productos específicos de isoformas COX :

Ver todos los productos específicos de isoformas Endogenous Metabolite :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.4 mM Compound: Gallic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay	[PMID: 27162124]
A549	IC₅₀	0.4 mM Compound: Gallic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay	[PMID: 27162124]
A549	IC₅₀	0.4 mM Compound: Gallic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27162124]
A549	IC₅₀	100 μM Compound: GA, Gallic acid	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 23291333]
BV-2	IC₅₀	>50 μM Compound: 27	Inhibition of iNOS-mediated NO production in LPS-induced mouse BV2 cells Inhibition of iNOS-mediated NO production in LPS-induced mouse BV2 cells	[PMID: 18926710]
Calu-6	IC₅₀	10 μM Compound: GA, Gallic acid	Cytotoxicity against human Calu6 cells Cytotoxicity against human Calu6 cells	[PMID: 23291333]
CCRF-CEM	CC₅₀	>250 μM Compound: 1	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation	[PMID: 25617695]
CCRF-CEM	EC₅₀	>50 μM Compound: 1	Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay	[PMID: 25617695]
CCRF-CEM	EC₅₀	>50 μM Compound: 1	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay	[PMID: 25617695]
CCRF-CEM	IC₅₀	>200 μM Compound: GA	Cytotoxicity against human CCRF-CEM cells after 48 hrs by neutral red assay Cytotoxicity against human CCRF-CEM cells after 48 hrs by neutral red assay	[PMID: 24568614]
CCRF-CEM	IC₅₀	>50 μM Compound: 0, Gallic acid	Cytotoxicity against human CEM cells after 24 hrs by MTT assay Cytotoxicity against human CEM cells after 24 hrs by MTT assay	[PMID: 18295493]
CCRF-CEM	IC₅₀	>50 μM Compound: 0, Gallic acid	Cytotoxicity against human CEM cells after 72 hrs by MTT assay Cytotoxicity against human CEM cells after 72 hrs by MTT assay	[PMID: 18295493]
Epithelial cell	IC₅₀	>20 μg/mL Compound: GA, Gallic acid	Cytotoxicity against rat epithelial cells Cytotoxicity against rat epithelial cells	[PMID: 23291333]
Erythrocyte	IC₅₀	0.59 mM Compound: 18	Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me	[PMID: 29631958]
Erythrocyte	IC₅₀	0.74 mM Compound: 18	Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet	[PMID: 29631958]
Fibroblast	IC₅₀	>20 μg/mL Compound: GA, Gallic acid	Cytotoxicity against rat fibroblast cells Cytotoxicity against rat fibroblast cells	[PMID: 23291333]
HCT-116	IC₅₀	41.8 μg/mL Compound: Gallic acid	Anticancer activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Anticancer activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 32731188]
HeLa	IC₅₀	26.3 μg/mL Compound: Gallic acid	Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 32731188]
HeLa	IC₅₀	358 μM Compound: GA, Gallic acid	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 23291333]
HL-60	IC₅₀	3.2 μg/mL Compound: gallic acid	Antioxidant activity in human HL60 cells assessed as reduction of cytochrome-c release Antioxidant activity in human HL60 cells assessed as reduction of cytochrome-c release	[PMID: 10650074]
HL-60	IC₅₀	300 μM Compound: GA, Gallic acid	Cytotoxicity against human HL60 cells Cytotoxicity against human HL60 cells	[PMID: 23291333]
HUVEC	IC₅₀	>294 μM Compound: 8	Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 48 hrs by fluorescence based assay Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated for 48 hrs by fluorescence based assay	[PMID: 37122550]
K562	IC₅₀	33 μM Compound: GA, Gallic acid	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 23291333]
K562	IC₅₀	4.75 μM Compound: GA, Gallic acid	Cytotoxicity against human imatinib-resistant K562 cells Cytotoxicity against human imatinib-resistant K562 cells	[PMID: 23291333]
KB	IC₅₀	13.2 μg/mL Compound: GA, Gallic acid	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 23291333]
L1210	IC₅₀	>50 μM Compound: 0, Gallic acid	Cytotoxicity against mouse L1210 cells after 48 hrs by MTT assay Cytotoxicity against mouse L1210 cells after 48 hrs by MTT assay	[PMID: 18295493]
L1210	IC₅₀	50 μM Compound: 0, Gallic acid	Cytotoxicity against mouse L1210 cells after 72 hrs by MTT assay Cytotoxicity against mouse L1210 cells after 72 hrs by MTT assay	[PMID: 18295493]
L929	IC₅₀	250 μM Compound: GA, Gallic acid	Cytotoxicity against mouse L929 cells Cytotoxicity against mouse L929 cells	[PMID: 23291333]
MCF7	IC₅₀	17.4 μM Compound: Gallic acid	Cytotoxicity against human ER-positive MCF7 cells assessed as decrease in cell proliferation at 12.5 to 100 uM incubated for 24 hrs Cytotoxicity against human ER-positive MCF7 cells assessed as decrease in cell proliferation at 12.5 to 100 uM incubated for 24 hrs	[PMID: 33711444]
P388	ED₅₀	0.7 μg/mL Compound: Gallic acid	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 3404159]
P388D1	IC₅₀	282 μM Compound: GA, Gallic acid	Cytotoxicity against human P388D1 cells Cytotoxicity against human P388D1 cells	[PMID: 23291333]
PLC-PRF-5	IC₅₀	387 μM Compound: GA, Gallic acid	Cytotoxicity against human PLC/PRF/5 cells Cytotoxicity against human PLC/PRF/5 cells	[PMID: 23291333]
RAW264.7	IC₅₀	>50 μM Compound: 13	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs by by Griess assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 2 hrs followed by LPS stimulation and measured after 24 hrs by by Griess assay	[PMID: 31419126]
RAW264.7	IC₅₀	631.6 μM Compound: gallic acid	Inhibition of LPS-induced NO production in mouse RAW264.7 cells assessed as reduction in nitrite level within 24 hrs by Griess reagent method Inhibition of LPS-induced NO production in mouse RAW264.7 cells assessed as reduction in nitrite level within 24 hrs by Griess reagent method	[PMID: 22560043]
RAW264.7	IC₅₀	69.25 μM Compound: 3a	Antagonist activity at TLR2 in mouse RAW264.7 cells assessed as PAM3CSK4-induced NO production measured after 24 hrs by Griess assay Antagonist activity at TLR2 in mouse RAW264.7 cells assessed as PAM3CSK4-induced NO production measured after 24 hrs by Griess assay	[PMID: 31255924]
Vero	IC₅₀	>1 μM Compound: 0, Gallic acid	Cytotoxicity against african green monkey VERO cells Cytotoxicity against african green monkey VERO cells	[PMID: 18295493]
Vero	IC₅₀	>299 μM Compound: 0, Gallic acid	Genotoxicity against african green monkey VERO cells Genotoxicity against african green monkey VERO cells	[PMID: 18295493]

In Vitro

Gallic acid is an antioxidant which can inhibit both COX-2^[1]. After 18 h treatment with Gallic acid, the number of viable neutrophils is dramatically decreased from 40.3% to 27.7%, highly comparable with 26.4% for untreated neutrophils. Gallic acid fails to attenuate isoproterenol-induced myocytolysis^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The food intake (2.6±0.08 g/day, p=0.69) and the body weight (2.5±0.69 g, p=0.76) of the Gallic acid group do not differ significantly from those of the control group (food intake; 2.41±0.14 g/day and the body weight; 2.83±0.84 g/day). The blood glucose tolerance in the Gallic acid group is significantly improved after 2 weeks of treatment. The blood glucose tolerance of the Gallic acid group after a treatment period of 2 weeks is also significantly better than that of the control group at 90 and 120 min ( p<0.05). The serum triglyceride concentration in the Gallic acid group (0.67±0.03 mM, p<0.05) is significantly reduced relative to that of the control group (1.08±0.20 mM). The total cholesterol concentration is similar in the control (3.19±0.27 mM) and Gallic acid (3.01±0.18 mM) groups^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

No. CAS 149-91-7
Appearance Solid
Peso molecular 170.12
Fòrmula C₇H₆O₅
Color White to off-white
SMILES

O=C(O)C1=CC(O)=C(O)C(O)=C1
Synonyms

3,4,5-Trihydroxybenzoic acid
Structure Classification
- Phenols
- Polyphenols
Initial Source
- Plants
- other families
- Microorganisms
- Endogenous metabolite
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

Publications (19)

All Histological Imaging/StainingELISAWBRT-PCRIHC

Sort by:

Journal Impact Factor

Biomaterials

Polyphenol-assisted facile assembly of bioactive nanoparticles for targeted therapy of heart diseases. [Abstract]

2021 Aug:275:120952. PMID: 34147720
Phytomedicine

Cinchonain Ia inhibits uric acid reabsorption by binding to the TRP-459 residue of the GLUT9 protein. [Abstract]

2026 May 14:157:158292. PMID: 42176511
Phytomedicine

Apigenin suppresses keratinocyte hyperproliferation and inflammation in psoriasis by inhibiting CDK2/E2F2 pathway. [Abstract]

2025 Aug:144:156486. PMID: 40516287
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Food Chem

Discovery of novel ascorbic acid derivatives and other metabolites in fruit of Rosa roxburghii Tratt through untargeted metabolomics and feature-based molecular networking. [Abstract]

2023 Mar 30;405(Pt A):134807. PMID: 36370576
J Transl Med

Gallic acid alleviates exercise-induced muscle damage by inhibiting mitochondrial oxidative stress and ferroptosis. [Abstract]

2025 Jan 8;23(1):30. PMID: 39780143

Gallic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Jan 8;23(1):30. [Abstract]

Hematoxylin and eosin (HE) and Sirius red staining revealed that after intervention with the ferroptosis inhibitor Fer-1 or Gallic acid (GA) (200 mg/kg/d, i.g.), the muscle fibers were more orderly arranged, and some muscle cells exhibited mild edema and a small amount of inflammatory cell infiltration.

Gallic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Jan 8;23(1):30. [Abstract]

Detection of IL-6, TNF-α, CK, LDH, Fe2⁺ and MDA levels significantly reduced treated with Gallic acid (GA) (200 mg/kg/d, i.g.) in skeletal muscle tissue by ELISA.

Gallic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Jan 8;23(1):30. [Abstract]

After Gallic acid (GA) (200 mg/kg/d, i.g.) intervention, both Piezo1 and COX2 were significantly decreased, and the expression of GPX4 and FTH1 was increased by Western blot.

Gallic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Jan 8;23(1):30. [Abstract]

Detection of Piezo1, GPX4, FTH1 and COX2 mRNA levels treated with Gallic acid (GA) (200 mg/kg/d, i.g.) in skeletal muscle tissue by RT-qPCR.

Gallic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Jan 8;23(1):30. [Abstract]

Immunohistochemical detection of Piezo1 and GPX4 expression treated with Gallic acid (GA) (200 mg/kg/d, i.g.) in skeletal muscle tissue of different groups of mice.
Pharmaceutics

Inhibition of SARS-CoV-2-Induced NLRP3 Inflammasome-Mediated Lung Cell Inflammation by Triphala-Loaded Nanoparticle Targeting Spike Glycoprotein S1. [Abstract]

2024 Jun 2;16(6):751. PMID: 38931873

Gallic acid purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2024 Jun 2;16(6):751. [Abstract]

A549 cells were pre-treated with active compounds (Gallic acid, Chebulagic acid, and Chebulinic acid) (0–20 µg/mL) for 24 h. Then, the cells were exposed to CoV2-SP (100 ng/mL) for 3 h. The IL-6 (A), IL-1β (B), and IL-18 secretions (C) in the culture supernatant were examined by ELISA.

Gallic acid purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2024 Jun 2;16(6):751. [Abstract]

Inhibitory effects of active compounds (Gallic acid, Chebulagic acid and Chebulinic acid) on the IL-6 (A), IL-1β (B), IL-18 (C), and NLRP3 gene expressions (D) in CoV2-SP-induced A549 cells. A549 cells were pre-treated with active compounds (gallic acid, chebulagic acid and chebulinic acid) (0–20 µg/mL) for 24 h. Then, the cells were exposed to CoV2-SP (100 ng/mL) for 3 h. The mRNA expressions were determined using RT-qPCR.
J Ethnopharmacol

Duhuo Jisheng decoction alleviates intervertebral disc degeneration by inhibiting nucleus pulposus cell pyroptosis via gallic acid-mediated downregulation of HIF-1α. [Abstract]

2026 Mar 1:358:120957. PMID: 41317810
Nat Prod Bioprospect

Exploring anti-SARS-CoV-2 natural products: dual-viral target inhibition by delphinidin and the anti-coronaviral efficacy of deapio platycodin D. [Abstract]

2025 Jun 13;15(1):39. PMID: 40512442
Eur J Pharmacol

Laccase-mediated functionalization of natamycin by gallic acids for the therapeutic effect on Aspergillus fumigatus keratitis. [Abstract]

2022 Jul 5:926:175041. PMID: 35597265
Pestic Biochem Physiol

Mechanistic insights into chlorogenic acid and caffeic acid as novel juvenile hormone antagonists. [Abstract]

2025 Dec:215:106655. PMID: 41162045
Plants

Metabolites of Prickly Rose: Chemodiversity and Digestive-Enzyme-Inhibiting Potential of Rosa acicularis and the Main Ellagitannin Rugosin D. [Abstract]

2021 Nov 20;10(11):2525. PMID: 34834888
Oncol Res

Gallic acid suppresses esophageal squamous cell carcinoma progression and enhances cisplatin chemosensitivity through IL-6/STAT3/Notch pathway. [Abstract]

2025 May 29;33(6):1473-1484. PMID: 40486873
J Sep Sci

Oriented Immobilization Coupled With Ligand Fishing Strategy for Rapid Discovery of Direct HMGB1 Inhibitors in Taxus wallichiana var. mairei. [Abstract]

2026 Apr;49(4):e70402. PMID: 41906428
Int J Parasitol Drugs Drug Resist

2026 Aug:31:100657. PMID: 42435521
J Immunol Res

Low-Dose Gallic Acid Administration Does Not Improve Diet-Induced Metabolic Disorders and Atherosclerosis in Apoe Knockout Mice. [Abstract]

2022 May 23;2022:7909971. PMID: 35652108
J Appl Toxicol

Evaluation of the effect of green tea and its constituents on embryo development in a zebrafish model. [Abstract]

2023 Feb;43(2):287-297. PMID: 35982029
Arch Oral Biol

Gallic acid promotes M2 macrophage polarization through mitochondrial oxidative phosphorylation in periodontitis. [Abstract]

2025 Jun:174:106237. PMID: 40107001
Res Sq

2024 Aug 26.

Solvente y solubilidad

In Vitro:

DMSO : ≥ 100 mg/mL (587.82 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 8.33 mg/mL (48.97 mM; ultrasonic and warming and heat to 60°C)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.8782 mL

29.3910 mL

58.7820 mL

5 mM

1.1756 mL

5.8782 mL

11.7564 mL

10 mM

0.5878 mL

2.9391 mL

5.8782 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (14.70 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (14.70 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil

Solubility: 20 mg/mL (117.56 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Cell Assay^[3]

Neutrophils are treated with 8?μg/mL Gallic acid in RPMI1640/10% FBS for 3, 6, 9, and 18?h. At the end of Gallic acid treatment, the cells are stained with Annexin V-FITC and PI according to manufacturer's instructions. Briefly, the cells are washed twice with ice-cold PBS and resuspended in 1× Binding Buffer at a concentration of 1×10⁶ cells/mL. Cell suspensions (1×10⁵ cells in 100?μL) are incubated with 5?μL of Annexin V-FITC and 10?μL PI in a 5?mL culture tube at room temperature for 20?min. The stained cells are immediately analyzed on flow cytometry system^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Five-week-old male C57BL/6 mice are used in this study. The animals are maintained in a temperature-controlled room at 22° C on a 12 h light-dark photocycle. The mice are divided into the control vehicle group and the Gallic acid group. For 2 weeks, the mice are administered intraperitoneal treatment on a daily basis with vehicle (10% alcohol, 10% tween 80, and 80% saline) alone or with 10 mg/kg Gallic acid. After this treatment, GTTs are again conducted, and the blood samples are taken for subsequent biochemical analysis. Over the experimental period, food intake and body weight are measured on a daily basis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (281 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Amaravani M, et al. COX-2 structural analysis and docking studies with gallic acid structural analogues. Springerplus. 2012 Dec;1(1):58. [Content Brief]

[2]. Bak EJ, et al. Gallic acid improves glucose tolerance and triglyceride concentration in diet-induced obesity mice. Scand J Clin Lab Invest. 2013 Dec;73(8):607-14. [Content Brief]

[3]. Cheng Y, et al. Plant Natural Products Calycosin and Gallic Acid Synergistically Attenuate Neutrophil Infiltration and Subsequent Injury in Isoproterenol-Induced Myocardial Infarction: A Possible Role for Leukotriene B4 12-Hydroxydehydrogenase? Oxid Med Cell Longev. 2015;2015:434052. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	5.8782 mL	29.3910 mL	58.7820 mL	146.9551 mL
	5 mM	1.1756 mL	5.8782 mL	11.7564 mL	29.3910 mL
	10 mM	0.5878 mL	2.9391 mL	5.8782 mL	14.6955 mL
	15 mM	0.3919 mL	1.9594 mL	3.9188 mL	9.7970 mL
	20 mM	0.2939 mL	1.4696 mL	2.9391 mL	7.3478 mL
	25 mM	0.2351 mL	1.1756 mL	2.3513 mL	5.8782 mL
	30 mM	0.1959 mL	0.9797 mL	1.9594 mL	4.8985 mL
	40 mM	0.1470 mL	0.7348 mL	1.4696 mL	3.6739 mL
DMSO	50 mM	0.1176 mL	0.5878 mL	1.1756 mL	2.9391 mL
	60 mM	0.0980 mL	0.4899 mL	0.9797 mL	2.4493 mL
	80 mM	0.0735 mL	0.3674 mL	0.7348 mL	1.8369 mL
	100 mM	0.0588 mL	0.2939 mL	0.5878 mL	1.4696 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Bioz

Keywords

Gallic acid

19 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Gallic acid

Publications Citing Use of MedChemExpress (MCE) Gallic acid

Ver todos los productos específicos de isoformas COX

Ver todos los productos específicos de isoformas Endogenous Metabolite